Clinical trials: Refractory Solid Cancer Patients Unexposed to Immunotherapy
Refractory Solid Cancer Patients Unexposed to Immunotherapy
T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy
This is a Phase 2, single-arm, multicenter study, evaluating the anti-tumor efficacy of tumor-infiltrating lymphocyte (TIL) directed tislelizumab monotherapy (also known as BGB-A317) for refractory solid tumors in approximately…
- Trial name
- NCT07300891
- Testing
- Tisleizumab(BGB-A317)
- Volunteers
- 72 people
- Sponsor
- Samsung Medical Center